M Bruggemann
Overview
Explore the profile of M Bruggemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
3159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Groger D, Sutton R, et al.
Leukemia
. 2023 Apr;
37(5):988-1005.
PMID: 37019990
Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401...
2.
Oberbeck S, Schrader A, Warner K, Jungherz D, Crispatzu G, von Jan J, et al.
Blood
. 2020 Dec;
136(24):2786-2802.
PMID: 33301031
T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic neoplasm. Differentiation stage and immune-effector functions of the underlying tumor cell are insufficiently characterized. Constitutive activation of the T-cell leukemia 1A (TCL1A) oncogene...
3.
Riva M, Bruggemann M, Li D, Perrier S, George C, Herrmann H, et al.
Anal Chem
. 2020 May;
92(12):8142-8150.
PMID: 32401497
Chemical ionization Orbitrap mass spectrometry (CI-Orbitrap) represents a promising new technique for gas-phase analysis in analytical and atmospheric chemistry mainly due to its very high mass resolving power. In this...
4.
Hess J, Kohl T, Kotrova M, Ronsch K, Paprotka T, Mohr V, et al.
Biotechnol Adv
. 2020 Mar;
41:107537.
PMID: 32199980
Next generation sequencing is in the process of evolving from a technology used for research purposes to one which is applied in clinical diagnostics. Recently introduced high throughput and benchtop...
5.
Thiesen I, Wehkamp U, Bruggemann M, Ritgen M, Murga Penas E, Klapper W, et al.
Br J Dermatol
. 2018 Sep;
180(1):227-228.
PMID: 30183072
No abstract available.
6.
Lhermitte L, Mejstrikova E, van der Sluijs-Gelling A, Grigore G, Sedek L, Bras A, et al.
Leukemia
. 2017 Nov;
32(4):874-881.
PMID: 29089646
Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide towards the relevant classification panel (T-cell acute lymphoblastic...
7.
Sellner L, Bruggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, et al.
Bone Marrow Transplant
. 2017 Apr;
52(4):656.
PMID: 28377595
No abstract available.
8.
Kotrova M, van der Velden V, van Dongen J, Formankova R, Sedlacek P, Bruggemann M, et al.
Bone Marrow Transplant
. 2017 Mar;
52(7):962-968.
PMID: 28244980
Minimal residual disease (MRD) monitoring via quantitative PCR (qPCR) detection of Ag receptor gene rearrangements has been the most sensitive method for predicting prognosis and making post-transplant treatment decisions for...
9.
Sellner L, Bruggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, et al.
Bone Marrow Transplant
. 2016 Dec;
52(4):544-551.
PMID: 27941777
Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking. We correlated minimal residual disease (MRD)...
10.
Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al.
Leukemia
. 2013 Dec;
28(6):1299-307.
PMID: 24342950
In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of...